On September 7th the FDA Will Review Amylyx Pharmaceuticals NDA for ALS Treatment
Amylyx Pharmaceuticals (AMLX) announced that the U.S. FDA Peripheral and Central Nervous System Advisory Committee (PCNSDAC) will reconvene to review the New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate and taurursodiol known also as ursodoxicoltaurine]) for the treatment of amyotrophic lateral sclerosis (ALS
This content is for paid subscribers.
Impacting News
August 11, 2022